Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.

Anaplastic lymphoma kinase Characteristics Epidermal growth factor receptor Genetic alterations Lung cancer Young patients

Journal

Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720

Informations de publication

Date de publication:
18 Dec 2023
Historique:
received: 06 11 2023
revised: 11 12 2023
accepted: 12 12 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 30 12 2023
Statut: aheadofprint

Résumé

The aim of this study was to analyze the clinical and genetic characteristics of young lung cancer cases, and to compare them with those of older cases. We used the Thoracic Tumors Registry (TTR) as a data source representative of lung cancer cases diagnosed in Spain, and included all cases registered until 9/01/2023 which had information on age at diagnosis or the data needed to calculate it. We performed a descriptive statistical analysis and fitted logistic regressions to analyze how different characteristics influenced being a younger lung cancer patient. A total of 26,336 subjects were included. Lung cancer cases <50 years old had a higher probability of being women (OR: 1.38; 95% CI: 1.21-1.57), being in stage III or IV (OR: 1.32; 95% CI: 1.08-1.62), not having comorbidities (OR: 5.21; 95% CI: 4.59-5.91), presenting with symptoms at diagnosis (OR: 1.53; 95% CI: 1.29-1.81), and having ALK translocation (OR: 7.61; 95% CI: 1.25-46.32) and HER2 mutation (OR: 5.71; 95% CI: 1.34-24.33), compared with subjects ≥50 years. Among subjects <35 years old (n=61), our study observed a higher proportion of women (59.0% vs. 26.6%; p<0.001), never smokers (45.8% vs. 10.3%; p<0.001), no comorbidities (21.3% vs. 74.0%; p<0.001); ALK translocation (33.3% vs. 4.4%; p<0.001) and ROS1 mutation (14.3% vs. 2.3%; p=0.01), compared with subjects ≥35 years. Lung cancer displays differences by age at diagnosis which may have important implications for its clinical management.

Identifiants

pubmed: 38160163
pii: S0300-2896(23)00407-6
doi: 10.1016/j.arbres.2023.12.005
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Cristina Candal-Pedreira (C)

Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela-IDIS), Santiago de Compostela, Galicia, Spain.

Alberto Ruano-Ravina (A)

Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela-IDIS), Santiago de Compostela, Galicia, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain. Electronic address: alberto.ruano@usc.es.

Virginia Calvo de Juan (V)

Oncology Department, Puerta de Hierro University Teaching Hospital, Majadahonda, Spain.

Manuel Cobo (M)

UGC Medical Oncology Intercenters, Regional and Virgen de la Victoria University Teaching Hospitals, Malaga, IBIMA, Malaga, Spain.

José Manuel Trigo (JM)

UGC Medical Oncology Intercenters, Regional and Virgen de la Victoria University Teaching Hospitals, Malaga, IBIMA, Malaga, Spain.

Delvys Rodríguez-Abreu (D)

Gran Canaria Island Hospital, Las Palmas de Gran Canaria, Spain.

Anna Estival (A)

Gran Canaria Island Hospital, Las Palmas de Gran Canaria, Spain.

Enric Carcereny (E)

Medical Oncology Department, Catalonian Oncology Institute, Badalona-Germans Trias i Pujol Hospital, B-ARGO Group, Spain.

Marc Cucurull (M)

Medical Oncology Department, Catalonian Oncology Institute, Badalona-Germans Trias i Pujol Hospital, B-ARGO Group, Spain.

Rafael López Castro (R)

Medical Oncology Section, Valladolid University Clinical Teaching Hospital, Spain.

Andrea Medina (A)

Medical Oncology Section, Valladolid University Clinical Teaching Hospital, Spain.

Rosario García Campelo (R)

Department of Oncology, A Coruña University Teaching Hospital Complex, Coruña, Spain.

Patricia Cordeiro González (P)

Department of Oncology, A Coruña University Teaching Hospital Complex, Coruña, Spain.

Amparo Sánchez-Gastaldo (A)

Virgen del Rocio University Teaching Hospital, Seville, Spain.

Joaquim Bosch-Barrera (J)

Catalonian Oncology Institute, Dr. Josep Trueta University Teaching Hospital, Girona, Spain.

Bartomeu Massutí (B)

Dr. Balmis University Teaching Hospital, Alicante Health Research and Biomedical Institute (ISABIAL), Alicante, Spain.

Manuel Dómine (M)

Jiménez Díaz Foundation University Hospital, IIS-FJD, Madrid, Spain.

Carlos Camps (C)

Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital and Precision Oncology Group (OncoGIR-Pro), Girona Biomedical Research Institute (IDIBGI), Girona, Spain.

Ana Laura Ortega (AL)

Jaén Hospital Complex, Jaén, Spain.

Alfredo Sánchez-Hernández (A)

Castellón Provincial Hospital, Castellón, Spain.

María Guirado Risueño (M)

Department of Oncology, Elche University General Teaching Hospital, Elche, Spain.

Edel Del Barco Morillo (E)

Medical Oncology Department, Salamanca University Healthcare Complex-IBSAL, Salamanca, Spain.

Alberto Garrido Fernández (A)

Álvaro Cunqueiro University Teaching Hospital, Vigo, Spain.

Mariano Provencio (M)

Oncology Department, Puerta de Hierro University Teaching Hospital, Majadahonda, Spain.

Classifications MeSH